Filings
| Filing | Date | Type | Filed with |
|---|
| BCAL Position on GSS-MAP Merger | Nov 18, 2026 | Acquisition or disposal | ASX |
|---|
| MAP: Proposed Merger with GSS not proceeding | Nov 17, 2026 | Acquisition or disposal | ASX |
|---|
| GSS: End of Proposed Merger with Microba Life Sciences | Nov 17, 2026 | Acquisition or disposal | ASX |
|---|
| Suspension from Quotation | Nov 16, 2026 | Trading halt or suspension | ASX |
|---|
| TOV: GSS - Panel Receives Application | Nov 13, 2026 | Other filings | ASX |
|---|
| Trading Halt Request | Nov 13, 2026 | Trading halt or suspension | ASX |
|---|
| Trading Halt | Nov 13, 2026 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Nov 12, 2026 | Trading halt or suspension | ASX |
|---|
| Cleansing Notice | Oct 28, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - MAP | Oct 27, 2026 | Financing | ASX |
|---|
| Letter to Shareholders, Notice of AGM & Proxy Form | Oct 27, 2026 | Meeting notice | ASX |
|---|
| Final Director's Interest Notice - Ian Frazer | Oct 26, 2026 | Ownership change notice | ASX |
|---|
| Final Director's Interest Notice - Gene Tyson | Oct 26, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - MAP | Oct 22, 2026 | Financing | ASX |
|---|
| Update on Commercial Terms for Proposed Merger with MAP | Oct 20, 2026 | Acquisition or disposal | ASX |
|---|
| Proposed issue of securities - MAP | Oct 19, 2026 | Financing | ASX |
|---|
| Proposed issue of securities - MAP | Oct 19, 2026 | Financing | ASX |
|---|
| Q1 FY27 Quarterly Activities Report & Appendix 4C | Oct 19, 2026 | Quarterly report | ASX |
|---|
| Q1 FY27 Quarterly Activities Report & Appendix 4C | Oct 19, 2026 | Quarterly report | ASX |
|---|
| Microba secures $2m placement and increases cost reductions | Oct 19, 2026 | Financing | ASX |
|---|
| Microba secures $2m placement and increases cost reductions | Oct 19, 2026 | Financing | ASX |
|---|
| Date of AGM and closing date for Director Nominations | Oct 13, 2026 | Meeting notice | ASX |
|---|
| Notification of cessation of securities - MAP | Oct 13, 2026 | Financing | ASX |
|---|
| Microba launches GI Navigator in Australia and the UK | Oct 6, 2026 | Operations update | ASX |
|---|
| Change in substantial holding | Sep 30, 2026 | Ownership change notice | ASX |
|---|
| Appointment of Interim Chief Executive Officer | Sep 24, 2026 | Management or board change | ASX |
|---|
| GSS and MAP agree to Commercial Terms for Merger | Sep 21, 2026 | Acquisition or disposal | ASX |
|---|
| 2026 Annual Report & Appendix 4E | Aug 30, 2026 | Annual report | ASX |
|---|
| 2026 Appendix 4G | Aug 30, 2026 | Other filings | ASX |
|---|
| 2026 Corporate Governance Statement | Aug 30, 2026 | Other filings | ASX |
|---|
| Genetic Signatures and Microba in Merger Discussions | Aug 25, 2026 | Acquisition or disposal | ASX |
|---|
| Change of Director's Interest Notice - Pasquale Rombola | Jul 31, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice - Prof Ian Frazer | Jul 31, 2026 | Ownership change notice | ASX |
|---|
| Cleansing Notice | Jul 29, 2026 | Financing | ASX |
|---|
| Notification regarding unquoted securities - MAP | Jul 28, 2026 | Other filings | ASX |
|---|
| Notification regarding unquoted securities - MAP | Jul 28, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - MAP | Jul 28, 2026 | Financing | ASX |
|---|
| Notification regarding unquoted securities - MAP | Jul 28, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - MAP | Jul 28, 2026 | Financing | ASX |
|---|
| Completion of Share Purchase Plan | Jul 27, 2026 | Financing | ASX |
|---|
| Q4 FY26 Quarterly Investor Presentation & Webinar | Jul 15, 2026 | Quarterly report | ASX |
|---|
| Investor presentation - path to cashflow breakeven | Jun 11, 2026 | Other filings | ASX |
|---|
| Pause in Trading | Jun 2, 2026 | Trading halt or suspension | ASX |
|---|
| Q3 FY26 Quarterly Investor Presentation & Webinar | Apr 29, 2026 | Other filings | ASX |
|---|
| Appendix 4D & FY26 Interim Report | Feb 25, 2026 | Interim report | ASX |
|---|
| Q2 FY26 Quarterly Investor Presentation & Webinar | Jan 28, 2026 | Other filings | ASX |
|---|
| Q2 FY26 Quarterly Activities Report & Appendix 4C | Jan 28, 2026 | Quarterly report | ASX |
|---|
| Microba receives $3 million R&D Tax Incentive Refund | Dec 2, 2025 | Results | ASX |
|---|
| Q1 FY26 Quarterly Investor Presentation & Webinar | Oct 27, 2025 | Quarterly report | ASX |
|---|
| Q1 FY26 Quarterly Activities Report & Appendix 4C | Oct 27, 2025 | Quarterly report | ASX |
|---|
| 2025 Annual Report & Appendix 4E | Aug 26, 2025 | Annual report | ASX |
|---|
| Q4 FY25 Quarterly Investor Presentation & Webinar | Jul 21, 2025 | Quarterly report | ASX |
|---|
| Q4 FY25 Quarterly Activities Report & Appendix 4C | Jul 21, 2025 | Quarterly report | ASX |
|---|
| Disclosure Document - Prospectus | Jun 27, 2025 | Offer document | ASX |
|---|
| Reinstatement to Quotation | Jun 23, 2025 | Trading halt or suspension | ASX |
|---|
| Strategic Investment & Equity Raise Presentation | Jun 23, 2025 | Other filings | ASX |
|---|
| Microba secures $14.5 million to drive clinical adoption | Jun 23, 2025 | Financing | ASX |
|---|
| Suspension from Quotation | Jun 23, 2025 | Trading halt or suspension | ASX |
|---|
| Trading Halt | Jun 18, 2025 | Trading halt or suspension | ASX |
|---|
| MetaPanel Pathogen Study Delivers Breakthrough Results | May 20, 2025 | Results | ASX |
|---|
| Landmark GI Study Results from over 4,600 patients | May 13, 2025 | Results | ASX |
|---|
| Q3 FY25 Quarterly Investor Presentation & Webinar | Apr 29, 2025 | Quarterly report | ASX |
|---|
| Q3 FY25 Quarterly Activities Report & Appendix 4C | Apr 29, 2025 | Quarterly report | ASX |
|---|
| Appendix 4D & FY25 Interim Report | Feb 25, 2025 | Interim report | ASX |
|---|
| Q2 FY25 Quarterly Investor Presentation & Webinar | Jan 28, 2025 | Quarterly report | ASX |
|---|
| Q2 FY25 Quarterly Activities Report & Appendix 4C | Jan 28, 2025 | Quarterly report | ASX |
|---|
| Trading Update | Nov 28, 2024 | Operations update | ASX |
|---|
| Microba receives $6 million R&D Tax Incentive Refund | Nov 17, 2024 | Other filings | ASX |
|---|
| Q1 FY25 Quarterly Activities Report & Appendix 4C | Oct 28, 2024 | Quarterly report | ASX |
|---|
| Q1 FY25 Quarterly Investor Presentation | Oct 28, 2024 | Other filings | ASX |
|---|
| 2024 Annual Report & Appendix 4E | Aug 28, 2024 | Annual report | ASX |
|---|
| Q4 FY24 Quarterly Investor Presentation & Webinar | Jul 24, 2024 | Quarterly report | ASX |
|---|
| Q4 FY24 Quarterly Activities Report & Appendix 4C | Jul 24, 2024 | Quarterly report | ASX |
|---|
| Completion of Autoimmune Program with Ginkgo Bioworks | Jun 27, 2024 | Operations update | ASX |
|---|
| Q3 FY24 Quarterly Investor Presentation | Apr 22, 2024 | Quarterly report | ASX |
|---|
| Q3 FY24 Quarterly Activities Report & Appendix 4C | Apr 22, 2024 | Quarterly report | ASX |
|---|
| Microba receives $6.08 million R&D Tax Incentive Refund | Apr 10, 2024 | Results | ASX |
|---|
| MetaPanel Launch Investor Presentation | Mar 12, 2024 | Other filings | ASX |
|---|
| MetaPanel Diagnostic Test Launched with Sonic Healthcare | Mar 12, 2024 | Other filings | ASX |
|---|
| Appendix 4D & FY24 Interim Report | Feb 27, 2024 | Interim report | ASX |
|---|
| Q2 FY24 Quarterly Investor Presentation | Jan 29, 2024 | Quarterly report | ASX |
|---|
| Q2 FY24 Quarterly Activities Report & Appendix 4C | Jan 29, 2024 | Quarterly report | ASX |
|---|
| Successful IBD Phase I Clinical Trial | Dec 6, 2023 | Other filings | ASX |
|---|
| Research Agreement Executed with IFF for Allergy Program | Dec 3, 2023 | Other filings | ASX |
|---|
| Autoimmune Stage 1 Screening Complete with Gingko Bioworks | Nov 27, 2023 | Operations update | ASX |
|---|
| Results of Retail Entitlement Offer | Nov 19, 2023 | Results | ASX |
|---|
| Fully Underwritten A$20 million Entitlement Offer | Oct 22, 2023 | Financing | ASX |
|---|
| Invivo Clinical Acquisition and Capital Raising Presentation | Oct 18, 2023 | Financing | ASX |
|---|
| Microba to acquire UK microbiome leader Invivo Clinical | Oct 18, 2023 | Acquisition or disposal | ASX |
|---|
| Q1 FY24 Quarterly Activities Report & Appendix 4C | Oct 18, 2023 | Quarterly report | ASX |
|---|
| Appendix 4E & Annual Report | Aug 29, 2023 | Annual report | ASX |
|---|
| Q4 FY23 Quarterly Investor Presentation | Jul 26, 2023 | Other filings | ASX |
|---|
| Q4 FY23 Quarterly Activities Report & Appendix 4C | Jul 26, 2023 | Quarterly report | ASX |
|---|
| First Distribution Agreement Executed with Sonic Healthcare | Jul 4, 2023 | Other filings | ASX |
|---|
| Microba Commences Phase I Clinical Trial for IBD Therapeutic | Jun 27, 2023 | Other filings | ASX |
|---|
| MRFF Grant Awarded to QUT, In Collaboration With Microba | Jun 27, 2023 | Other filings | ASX |
|---|
| Microba receives two AusIndustry Advanced Overseas Findings | Jun 14, 2023 | Other filings | ASX |
|---|
| Q3 FY23 Quarterly Investor Presentation | Apr 19, 2023 | Other filings | ASX |
|---|
| Q3 FY23 Quarterly Activities Report & Appendix 4C | Apr 19, 2023 | Quarterly report | ASX |
|---|
| SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia | Apr 12, 2023 | Other filings | ASX |
|---|
| Microba Receives Ethics Approval for Phase 1 Clinical Trial | Mar 29, 2023 | Other filings | ASX |
|---|
| SYNLAB Agreements Signed in Turkiye and Czech Republic | Mar 1, 2023 | Other filings | ASX |
|---|
| Microba Launches Next Generation Healthcare Testing | Feb 27, 2023 | Other filings | ASX |
|---|
| H1 FY23 Interim Report | Feb 22, 2023 | Interim report | ASX |
|---|
| US Distribution Agreement Signed with Luminary Health | Feb 6, 2023 | Other filings | ASX |
|---|
| Positive first animal data for Cancer Program | Jan 31, 2023 | Other filings | ASX |
|---|
| Q2 FY23 Quarterly Activities Report & Appendix 4C | Jan 29, 2023 | Quarterly report | ASX |
|---|
| SYNLAB Agreements Signed in Italy and Portugal | Dec 7, 2022 | Other filings | ASX |
|---|
| Sonic Investment & Partnership Investor Presentation | Nov 28, 2022 | Other filings | ASX |
|---|
| Sonic Acquires 19.9% Microba Stake and Enters Partnership | Nov 28, 2022 | Acquisition or disposal | ASX |
|---|
| Microba receives $2.62m R&D Tax Incentive refund | Oct 31, 2022 | Other filings | ASX |
|---|
| Q1 FY23 Quarterly Activities Report & Appendix 4C | Oct 26, 2022 | Quarterly report | ASX |
|---|
| Microba, SYNLAB Extend & Expand Distribution | Oct 19, 2022 | Other filings | ASX |
|---|
| Therapeutic Program Advancement | Aug 30, 2022 | Other filings | ASX |
|---|
| Investor Presentation - FY22 Update Annual Results | Aug 29, 2022 | Other filings | ASX |
|---|
| Q4 FY22 Quarterly Activities Report & Appendix 4C | Jul 19, 2022 | Quarterly report | ASX |
|---|
| G42 Healthcare Partnership Commences Operation | Jun 27, 2022 | Other filings | ASX |
|---|
| Microba & Ginkgo Commence Therapeutics Program | Jun 7, 2022 | Other filings | ASX |
|---|
| Partnership signed with nib-backed Midnight Health | May 25, 2022 | Other filings | ASX |
|---|
| Microba Accelerates Cancer Program | May 5, 2022 | Other filings | ASX |
|---|